BOL-DP-o-04

BOL-DP-o-04 is a sublingual formulation of medical cannabis developed by Breath of Life (BOL) Pharma for the treatment of pain, including pain associated with diabetic neuropathy and chronic pain in patients undergoing hemodialysis. It is classified as an analgesic and cannabinoid. The drug acts as a **cannabinoid receptor modulator**, containing both trans-delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:6 ratio. Clinical studies have shown that short-term use was generally well tolerated in patients with end-stage kidney disease on hemodialysis, with most adverse events being mild to moderate and resolving spontaneously[1][3][5]. The product is not considered a new molecular entity.

Other names

BOL-DP-o-04 + SCOBOL-DP-o-04 + SOC